Nasopharyngeal carcinoma secondary prevention: Difference between revisions
No edit summary |
YazanDaaboul (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers by routine TSH measurement is recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for nasopharyngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | ||
Line 25: | Line 22: | ||
*Every 2-6 months for 2nd year after treatment | *Every 2-6 months for 2nd year after treatment | ||
*Every 4-8 months between 3 and 5 years after treatment | *Every 4-8 months between 3 and 5 years after treatment | ||
*Annually | *Annually thereafter | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
Line 52: | Line 49: | ||
|- | |- | ||
|} | |} | ||
<sup>Table adapted from Pfister DG, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23.<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref></sup> | |||
==References== | ==References== |
Revision as of 15:46, 29 September 2015
Nasopharyngeal carcinoma Microchapters |
Differentiating Nasopharyngeal carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Nasopharyngeal carcinoma secondary prevention On the Web |
American Roentgen Ray Society Images of Nasopharyngeal carcinoma secondary prevention |
Risk calculators and risk factors for Nasopharyngeal carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers by routine TSH measurement is recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively.
Secondary Prevention
Follow up after treatment
Patients treated for nasopharyngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1]
Follow up | Description |
---|---|
|
|
|
|
|
Scans are performed at routine intervals as follows:
|
|
|
|
|
Table adapted from Pfister DG, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23.[1]
References
- ↑ 1.0 1.1 Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.